UDCA

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)

Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis

Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis

Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid

Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin

Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA

Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)

Pharmacokinetic Investigation of UDCA in Bile and Serum

Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis

Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid

Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases